On 23 March 2026, I was invited to give a lecture at IQWiG’s headquarters in Cologne, Germany. IQWiG is the German HTA body and is widely recognized for the high quality of its assessments and reports. It has shaped the way drugs and trials are evaluated and is actively involved in how they will be assessed in the future, including through joint evaluations within the European Union.
Here is my full talk. I would like to thank the IQWiG team again for the invitation, for their warm welcome, and for their outstanding work. You should definitely follow IQWiG’s activities and read their reports, which may contain more data than what is available in publications.
+ At 41:40, get a glimpse of what can be done with the new V2 version of the BREAKING-ICE App© and its Assistant-KM companion app, with the updated sensitivity analysis based on the 5-year follow-up of the NATALEE trial.
